Banner
Reliable information for medical professionals

Resources

Watch: Welcome, Case Studies, Medical Symposia

Bill Bro, CEO

Welcome Message


Bill Bro, CEO
 
KidneyCancer.com

Sandy Srinivas, M.D.
Sandy Srinivas, M.D.

The Role of Biopsy 
For Patients with a 
Renal Mass

John T. Leppert, MD

John T. Leppert, M.D.

 

The Role of Biopsy 
For Patients with a 
Renal Mass

Benjamin I. Chung, M.D.

Benjamin I. Chung, M.D

 

Surgical Options

Andrea Harzstark, M.D.
Andrea Harzstark, M.D.


Choice of Front Line Trials

 

Sandy Srinivas, M.D.
Sandy Srinivas, M.D.


Furture Trials

 

David Minor, M.D.
D
avid Minor, MD


Immunotherapy

 


 

a1-heckman
Jennifer Heckman, M.D., M. PH.


Case Presentation

a2-jewett
Michael Jewett, M.D.


Update on Active 
Surveillance

a3-lee
Fred Lee, M.D.


Debate: RFA/Microwave 
is Best for Ablation Patients

j4-atkins

Michael Atkins, M.D.


Defining our Needs in RCC

a4-atwell
Thomas Atwell, M.D.


Debate: CRYO is Best 
for Ablation Patients

a6-lane
Brian Lane, M.D.


CON-Renal Mass Biopsy

a8-uzzo
Robert Uzzo, M.D.
, FACS


Summary and Case 
Presentations for 
Management of Small 
Renal Mass

b1-kim
Simon Kim, M.D.

 

b2-abouassaly
Robert Abouassaly, M.D.


Chronic Kidney Disease 
and Competing 
Comorbidities in 
the Management of 
Localized RCC

b3-thompson
R. Houston Thompson, M.D.


Partial vs Radical 
Nephrectomy for 
Larger Renal Masses

b4-abel
E. Jason Abel, M.D.


Update on Management 
of IVC Thrombus

b5-margulis
Vitaly Margulis, M.D.


Role of Lymph Node 
Dissection

b6-master
Viraj Master, M.D.


Follow-up Patients 
After Surgical Treatment

b7-campbell
Steven Campbell, M.D., PhD


Summary and Case 
Presentation for 
Management of 
Localized/Locally 
Advanced RCC

b8-wood
Chirstopher Wood, M.D., FACS


Novick Lecture

c1-fan
Alice Fan, M.D.


Nano-Scale Proteomic 
Profiling Define Diagnostic 
Signatures and Biomarkers 
of Therapeutic Activity in 
Patients with RCC

c2-mckay
Ranay McKay, M.D.


Impact of Bone 
Metastases and 
Bishophonate use in 
Patients with Metastatic 
Renal Cell Carcinoma 
Treated with Targeted 
Therapy:  Results from 
polled clinical Trials

c3-leppert
John Leppert, M.S.


Utilization of Cytoreductive 
Nephrectomy and Patient 
Survival in the Targeted 
Therapy Era

c4-cost
Nicholas Cost, M.D.


The Initial Experience 
with RENAL Nephrometry 
in Children, Adolescents 
and Young Adults with 
Renal Tumors

c5-wood
Christopher Wood, M.D., FACS


An Ongoing International 
Phase 3 Randomized Trial 
of Autologous Dendritic 
Cell Immunotherapy 
(AGS003) Plus Standard 
Treatment in Advanced 
Renal Cell Carcinoma (RCC)

c6-choueiri
Toni Choueiri, M.D.


A Phase 3 Randomized 
Study of Cabozantinib 
(XL184) vs Everolimus 
in Subjects with Clear 
Cell Renal Carcinoma (METEOR)

c7-gore
Martin Gore, MBBS, PhD, FRCP


A Phase 3 Comparative Study 
of Nivolumab (anti-PD-1; 
BMS-936558; ONO-4538) 
vs Everolimus in Patients With 
Advanced or Metastatic Renal 
Cell Carcinoma (mRCC) 
Previously Treated with 
Anti-Angiogenic Therapy

d1-kim
William Kim, M.D.


Exploration of the 
RCC Kinome for Novel 
Therapeutic Targets

d2-davis
Ian Davis, M.D.


Chromantin Biology 
and RCC

d3-mier
James Mier, M.D.


HGDM2 A Therapeutic 
Target

d4-tannir
Nizar Tannir, M.D., FACP


New Insights in Biology of 
Non-Clear Cell RCC

d5-brugarolas
James Brugarolas, M.D., PhD


Translational Biology of 
RCC What's Next

e1-mckay
Rana McKay, M.D.

 

e3-vaishampayan
Ulka Vaishampayan, M.D.


AUS in Advanced RCC an
Dose Education in Clinical Practice

e4-molina
Ana Molina, M.D.


Management of 
Advanced RCC 
Patients with Renal 
and Liver Dysfunction

e5-pal
Sumanta Pal, M.D.


AEs and Rationale for 
Treatment Selection 
in Advanced RCC

f1-haas
Naomi Haas, M.D.


Special Lecture: Status 
of Adjuvant Therapy in 
High-Risk RCC

f3-powles
Thomas Powell, M.D., MBBS, MRCP


Debate: Targeted 
Therapy First

f4-bratslavsky
Gennady Bratslavsky, M.D.


Debate:  Cytroreductive Nephrectomy First

f5-larochelle
Jeffrey LaRochelle, M.D.


Lymph Node Dissection 
Durring Cytoreductive Nephrectomy

f6-karam
Jose Karam, M.D.


Role of Metastasectomy

f7-cheville
John Chevelle, M.D.


RCC: The Role of the Pathologist

f8-leibovich
Bradley Leibovich, M.D.


Summary and Case 
Presentation for 
Surgery in Metastatic Disease

g1-nagiar
Yana Najjar, M.D.

 

g2-drake
Charles Drake, M.D., PhD


Immune System as a 
Therapeutic Target in RCC

g3-finke
James Finke, PhD


Tumor Microenvironment
in RCC

g4-sharma
Padmanee Sharma, M.D.


Targeting CTLA4 in RCC: 
Rational and Current Data

g5-storkus
Walter Storkus, PhD


Vaccines in RCC: 
Rational and Current Data

g6-freeman
Gordon Freeman, PhD


PD1/PDL1

g7-mcdermott
Davide McDermott, M.D.


Immune Biomarkers 
in RCC: What, When 
and How

i1-rodriguez
Cristina Suarez Rodriguez, M.D.

 

 

i2-hutson
Thomas Hutson, DO, PharmaD, FACP


Existing Clinical Data of 
Second-Line/Greater 
Therapy in Advanced RCC

i3-grunwald
Victor Grunwald, M.D.


Update in the Biology of Resistance Disease

i4-giaccia
Amato Garcia, PhD


Novel Agents from 
Synthetic Lethal 
Screens

i5-illopoulos
Othon Iliopoulos, M.D.


Current Status of HIF 
Biology in RCC

i6-ho
Thai Ho, M.D., PhD


Emerging Targets 
in RCC

j1-rini
Brian Rini, M.D.


How to Proceed with 
Clinical Research 
Development

j2-jonasch
Eric Jonasch, M.D.


Preoperative Strategies 
Under Considerations

j3-mims

Martha Mims, M.D., PhD


Advanced RCC Trial

 

kca video thumb 0014 image 002
78 YO White Female


2013 
M. D. Anderson 
Patient Meeting

kca video thumb 0009 image 008 copy
63 YO White Male


2013 
M. D. Anderson 
Patient Meeting

kca video thumb 0013 image 003
51 YO


2013 
M. D. Anderson 
Patient Meeting

kca video thumb 0015 image 001
62 YO White Female


2013 
M. D. Anderson 
Patient Meeting

kca video thumb 0012 image 004
50 YO White Male


2013 
M. D. Anderson 
Patient Meeting

kca video thumb 0010 image 008
67 YO


2013 
M. D. Anderson 
Patient Meeting

kca video thumb 0011 image 006
66 YO White Male


2013 
M. D. Anderson 
Patient Meeting

kca video thumb 0005 image 0011
59 YO White Male


2013 
M. D. Anderson 
Patient Meeting

kca video thumb 0001 image 0015
58 YO White Female


2013 
M. D. Anderson 
Patient Meeting

kca video thumb 0002 image 0014]
55 YO White Male


2013 
M. D. Anderson 
Patient Meeting

kca video thumb 0007 image 0010
45 YO White Female


2013 
M. D. Anderson 
Patient Meeting

kca video thumb 0008 image 009
74 YO


2013 
M. D. Anderson 
Patient Meeting

kca video thumb 0000 image 0016
59 YO Hispanic Male


2013 
M. D. Anderson 
Patient Meeting

kca video thumb 0004 image 0012
57 YO AA Female


2013 
M. D. Anderson 
Patient Meeting

kca video thumb 0009 image 008 copy
53 YO Black Female


2013 
M. D. Anderson 
Patient Meeting

kca video thumb 0003 image 0013
52 YO White Female


2013 
M. D. Anderson 
Patient Meeting

kca video thumb 0006 image 0010 copy
51 YO Hispanic Male


2013 
M. D. Anderson 
Patient Meeting

kca video thumb 0010 image 008
Questions & Answers


2013 
M. D. Anderson 
Patient Meeting

kca video thumb 0008 image 009
Kidneycancer.org


2013 
M. D. Anderson 
Patient Meeting
John Fitzpatrick
John Fitzpatrick, M.D.

The TNM Staging System: 
A Critical Analysis

Peter Clark
Peter Clark, M.D., Ph.D.

Preoperative Nutritional 
Status and Survival
after Surgery

Thomas Powles
Thomas Powles, M.D.

Detection of Bone Disease

Tatjana Traub-Weidinger, M.D.
Tatjana Traub-Weidinger, M.D.

Is There a Role for PET-CT 
in mRCC?

Alex Bex, M.D>, Ph.D.
Axel Bex, M.D., Ph.D.

Cytoreductive Nephrectomy: 
Survival Impact of Surgery 
in mRCC

Jean Jaques Patard, M.D., Ph.D.
Jean Jaques Patard, M.D., Ph.D.

Natural History of Patients 
with Local Recurrence after 
Nephrectomy for Localized RCC

Isaac Witz, M.D.
Isaac Witz, M.D.

The Tumor
Microenvironment 
in RCC?

Sergio Quesada, M.D.
Sergio Quezada, M.D.

Immune Biology of Cancer 
Revisited

James Larkin, Ph.D., MRCP
James Larkin, Ph.D., MRCP

Mechanisms of Resistance

 

Michael Atkins, M.D.
Michael Atkins, M.D. 

Single Nucleotide Polymorphisms 
in RCC: Clinically Relevant 
Implications for Daily Practice?

 

Manuela Schmindinger, M.D.
Manuela Schmindinger, M.D.

Bone Targeting

 

Vincenzo Ficarra, M.D., Ph.D.
Vincenzo Ficara, M.D., Ph. D.

Papillary RCC: the SATURN 
project

 

Tim O'Brien, M.D.
Tim O'Brien, M.D.

IVC Thrombus Surgery: 
What's New, What's Up, 
What's Next

 

Vincenzo Ficarra, M.D., Ph.D.
Vincenzo Ficarra, Ph.D., M.D.

Strategies for Robotic Surgery 
in RCC

 

Steven Joniau, M.D.
Steven Joniau, M.D.

Stage 1b RCC: Partial 
Nephrectomy the New 
Standard-PRO

 

Didier Jacqmim
Didier Jacquim, M.D.

Stage 1b RCC: Partial 
Nephrectomy the New 
Standard-CON

 

Christopher Wood
Christopher Wood, M.D., FACS

Neoadjuvant Treatment in 
Advanced RCC: What is 
Next Step?

Bradley Leibovich, M.D., FACS
Bradley Leibovich, M.D., FACS

Nomograms and Scores

 

Masatoshi Eto
Masatoshi Eto, M.D., Ph.D. 

The Role of IFN-alpha 
in 2012: Importance of 
Targeting the Right Patient

 

Rosalie Fisher
Rosalie Fisher, M.D.

Observation is a Valid 
Approach in mRCC

David McDermott
David McDermott, M.D.

Identification of Potential 
IL-2 Responders: the 
Ultimate Ambition?

Stephane Oudard, M.D. Ph. D.
Stephane Oudard, M.D., Ph. D.

Vaccines in the Era of TKI:
Much Ado About Nothing?

Sergio Bracarda
Sergio Bracarda. M.D.

Case: First-line Treatment 
in a Multimorbid Patient

Alain Ravaud
Alain Ravaud M.D., Ph. D.

Case: First-line Treatment in 
a Patient with High Tumor 
Burden

Fabio Calabro, M.D.
Fabio Calabro, M.D.

Case: First-line Treatment 
Strategy in a Patient with 
Low Tumor Burden

Joaquim Bellmunt, M.D.
Joaquim Bellmunt, M.D.

Case: First-line Treatment 
in a Patient with Sarcomatoid 
RCC

Seva Matveev, M.D.
Seva Matveev, M.D.

Resection of Multiple 
Metastases from RCC

Eric Lartigau, Ph.D.
Eric Lartigau, Ph.D.

Stereotactic Radiosurgery 
for Extracranial Metastases 
is a Valid Approach in the 
Setting of Metastatic Disease

Bertram Häussler, M.D., Ph.D.
Bertram Haussler, M.D., Ph.D.

Keynote Lecture: Novel Cancer 
Agents Will NOT Cause a 
Breakdown of Health Care 
Systems: Results of the 
IGES-Study

 

Manuela Schmidinger, M.D.
Manuela Schmidinger, M.D.

Single Nucleotide Polymorphisms 
in RCC: Clinically Relevant 
Implications for Daily Practice?

 

Luis Aparicio, M.D.
Luis Aparicio, M.D.

Management of Fatigue

 

Jutta Bergler-Klein, M.D.
Jutta Bergler-Klein, M.D.

Understanding the Mechanisms 
of Hypertension and Management

 

Cesary Szczylik, M.D., Ph. D.
Cesary Szczylik, M.D.

Management of Anorexia

 

Brian Rini, M.D.
Brian I. Rini, M.D.

Axitinib IS the New Standard
of Care in 2nd-line: PRO

 

Tim Eisen, M.D.
Tim Eisen, M.D.

Axitinib IS the New 
Standard of Care in 
2nd-line: CON

 

Laure Fournier, M.D.
Laure Fournier M.D.

Stage 1b RCC: Partial 
Nephrectomy the New 
Standard-CON

 

Michael B. Atkins, M.D.
Michael B. Atkins, M.D.

New Targets, New Pathways

Sylvie Negrier, M.D.
Sylvie Negrier, M.D.

Combination Strategies: 
When and How?

 

Camillo Porta, M.D.
Camillo Porta, M.D.

Should Response to 1st-line 
Agents Guide the Choice 
of Treatment in 2nd-line?